Compare Stocks: FLNA, CRDL, NERV, and BGM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$10.07 -1.3%	$8.44	$6.45 ▼ $303.00	$129.41M	1.85	6,747 shs	5,314 shs
CRDL Cardiol Therapeutics	$1.20 +1.7%	$1.76	$0.88 ▼ $2.34	$140.34M	0.88	1.65 million shs	2.03 million shs
FLNA Cassava Sciences	$0.74 -3.4%	$0.86	$0.67 ▼ $4.98	$37.17M	-0.65	5.84 million shs	323,327 shs
NERV Minerva Neurosciences	$2.52 -12.8%	$4.03	$2.39 ▼ $12.46	$137.99M	-0.1	161,811 shs	185,460 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-0.97%	+4.30%	+27.57%	+7.88%	-96.46%
CRDL Cardiol Therapeutics	+1.69%	-8.40%	-39.85%	+8.11%	+14.29%
FLNA Cassava Sciences	-3.39%	-15.03%	-3.78%	-32.42%	-81.87%
NERV Minerva Neurosciences	-12.80%	-26.53%	-39.28%	-41.67%	-0.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$10.07 -1.3%	$8.44	$6.45 ▼ $303.00	$129.41M	1.85	6,747 shs	5,314 shs
CRDL Cardiol Therapeutics	$1.20 +1.7%	$1.76	$0.88 ▼ $2.34	$140.34M	0.88	1.65 million shs	2.03 million shs
FLNA Cassava Sciences	$0.74 -3.4%	$0.86	$0.67 ▼ $4.98	$37.17M	-0.65	5.84 million shs	323,327 shs
NERV Minerva Neurosciences	$2.52 -12.8%	$4.03	$2.39 ▼ $12.46	$137.99M	-0.1	161,811 shs	185,460 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-0.97%	+4.30%	+27.57%	+7.88%	-96.46%
CRDL Cardiol Therapeutics	+1.69%	-8.40%	-39.85%	+8.11%	+14.29%
FLNA Cassava Sciences	-3.39%	-15.03%	-3.78%	-32.42%	-81.87%
NERV Minerva Neurosciences	-12.80%	-26.53%	-39.28%	-41.67%	-0.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	1.00	Sell	N/A	N/A
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	733.33% Upside
FLNA Cassava Sciences	2.00	Hold	$5.00	572.59% Upside
NERV Minerva Neurosciences	2.00	Hold	$10.33	310.05% Upside

Current Analyst Ratings Breakdown

Latest FLNA, CRDL, NERV, and BGM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/9/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/23/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$9.00
9/22/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
8/6/2026	BGM BGM Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (E+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$37.92M	3.37	N/A	N/A	$121.05 per share	0.08
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$19.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
FLNA Cassava Sciences	-$90.97M	-$0.87	N/A	N/A	N/A	N/A	-58.78%	-36.74%	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)

Latest FLNA, CRDL, NERV, and BGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	NERV Minerva Neurosciences	-$0.14	N/A	N/A	N/A	N/A	N/A
8/28/2026	Q2 2026	BGM BGM Group	N/A	-$0.30	N/A	-$0.0050	N/A	$12.15 million
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
7/29/2026	Q2 2026	FLNA Cassava Sciences	N/A	-$0.18	N/A	-$0.18	N/A	N/A
7/21/2026	Q4 2025	BGM BGM Group	N/A	-$80.70	N/A	-$2.6850	N/A	$11.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.25	0.73
CRDL Cardiol Therapeutics	N/A	5.55	5.55
FLNA Cassava Sciences	N/A	2.08	2.08
NERV Minerva Neurosciences	N/A	20.15	20.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
CRDL Cardiol Therapeutics	12.49%
FLNA Cassava Sciences	38.05%
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
CRDL Cardiol Therapeutics	5.25%
FLNA Cassava Sciences	4.60%
NERV Minerva Neurosciences	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	471	12.69 million	5.25 million	N/A
CRDL Cardiol Therapeutics	18	118.93 million	112.69 million	Not Optionable
FLNA Cassava Sciences	30	48.31 million	46.09 million	Optionable
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable

FLNA, CRDL, NERV, and BGM Headlines

Recent News About These Companies

Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 10.02%

4 hours ago | aaii.comA

Minerva Neurosciences, Inc (NASDAQ:NERV) Stock Now Rated "Reduce" by Wall Street Analysts

October 8, 2026 | americanbankingnews.com

Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Analysts

October 3, 2026 | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average - Here's Why

October 2, 2026 | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200-Day Moving Average - Here's Why

September 16, 2026 | marketbeat.com

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

August 28, 2026 | globenewswire.com

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

August 7, 2026 | globenewswire.com

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

June 1, 2026 | globenewswire.com

Minerva Neurosciences Launches ATM Offering to Fund Trial

May 27, 2026 | tipranks.com

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

May 20, 2026 | zacks.com

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 18, 2026 | globenewswire.com

Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | finanznachrichten.de

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | globenewswire.com

Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69

April 28, 2026 | msn.com

Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation

April 16, 2026 | msn.com

Minerva launched with New Outperform at Citizens on schizophrenia candidate

April 15, 2026 | seekingalpha.com

Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

April 6, 2026 | tipranks.com

Minerva Announces Leadership Transition

April 2, 2026 | globenewswire.com

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

March 31, 2026 | globenewswire.com

Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia

March 31, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA, CRDL, NERV, and BGM Company Descriptions

BGM Group NASDAQ:BGM

$10.06 -0.14 (-1.32%)

Closing price 10/13/2026 03:57 PM Eastern

Extended Trading

$10.06 0.00 (0.00%)

As of 10/13/2026 07:30 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Cardiol Therapeutics NASDAQ:CRDL

$1.20 +0.02 (+1.69%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$1.29 +0.09 (+7.83%)

As of 04:01 AM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cassava Sciences NASDAQ:FLNA

$0.74 -0.03 (-3.39%)

As of 10/13/2026 04:00 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Minerva Neurosciences NASDAQ:NERV

$2.52 -0.37 (-12.80%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$2.52 0.00 (-0.20%)

As of 10/13/2026 07:55 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FLNA, CRDL, NERV, and BGM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FLNA, CRDL, NERV, and BGM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FLNA, CRDL, NERV, and BGM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA, CRDL, NERV, and BGM Company Descriptions

BGM Group NASDAQ:BGM

Cardiol Therapeutics NASDAQ:CRDL

Cassava Sciences NASDAQ:FLNA

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FLNA, CRDL, NERV, and BGM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FLNA, CRDL, NERV, and BGM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FLNA, CRDL, NERV, and BGM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA, CRDL, NERV, and BGM Company Descriptions

BGM Group NASDAQ:BGM

Cardiol Therapeutics NASDAQ:CRDL

Cassava Sciences NASDAQ:FLNA

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools